Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Crude oil prices display bullish short-term reversals, resulting in bullish price and RS reversals for global Energy stocks -- add exposure. From a macro perspective, despite some mild price deterioration recently on major indexes around the globe, our outlook remains unchanged and we remain neutral yet constructive overall. Market dynamics remain largely constructive and we continue to see attractive opportunities in many countries/regions such as Japan, China (Shanghai Composite), Europe, India, and Canada, to name a few.

Crude oil prices display bullish short-term reversals, resulting in bullish price and RS reversals for global Energy stocks -- add exposure. From a macro perspective, despite some mild price deterioration recently on major indexes around the globe, our outlook remains unchanged and we remain neutral yet constructive overall. Market dynamics remain largely constructive and we continue to see attractive opportunities in many countries/regions such as Japan, China (Shanghai Composite), Europe, India, and Canada, to name a few.

Global Energy Sector Improving -- Buying Reliance Industries Ltd, Several Others

Equity Analyst, LightStream Research

Oshadhi Kumarasiri

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kirin-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:16977:1" rel="noopener">Kirin Holdings (2503 JP)</a>’s 2Q21 results, released yesterday was rather disappointing with revenue and operating profit falling below the consensus by 1.5% and 67% respectively.</li>
<li>The company’s revenue grew 1.5% YoY to ¥454.7bn compared to -3.6%, -2.7%, -4.1% and -9.6% in 1Q21, 4Q20, 3Q20 and 2Q20, respectively.</li>
<li>The operating profit decreased 40.9% YoY to ¥13.8bn, compared to ¥28.0bn, ¥23.6bn, ¥54.9bn and ¥23.4bn in 1Q21, 4Q20, 3Q20 and 2Q20, respectively.</li>
<li>The full-year revenue and normalised operating profit guidance were lowered by 0.5% and 5.6% respectively and the new 2021 revenue and normalised operating profit guidance stood at ¥1,870bn and ¥170bn compared to consensus revenue and OP of ¥1,862bn and ¥152.2bn, respectively.</li>
<li>Nevertheless, the price reaction to the earnings miss was rather subdued with shares only falling around 2.1%. This would normally concern us. However, Kirin is currently trading near the 52-week low and it appears that downside risks such as the troubles regarding the Myanmar JV and the overall market weaknesses due to COVID-19 are mostly priced in the current share price. Therefore, we would buy Kirin at these levels.</li>
</ul>



Kirin Holdings (2503 JP)’s 2Q21 results, released yesterday was rather disappointing with revenue and operating profit falling below the consensus by 1.5% and 67% respectively.
The company’s revenue grew 1.5% YoY to ¥454.7bn compared to -3.6%, -2.7%, -4.1% and -9.6% in 1Q21, 4Q20, 3Q20 and 2Q20, respectively.
The operating profit decreased 40.9% YoY to ¥13.8bn, compared to ¥28.0bn, ¥23.6bn, ¥54.9bn and ¥23.4bn in 1Q21, 4Q20, 3Q20 and 2Q20, respectively.
The full-year revenue and normalised operating profit guidance were lowered by 0.5% and 5.6% respectively and the new 2021 revenue and normalised operating profit guidance stood at ¥1,870bn and ¥170bn compared to consensus revenue and OP of ¥1,862bn and ¥152.2bn, respectively.
Nevertheless, the price reaction to the earnings miss was rather subdued with shares only falling around 2.1%. This would normally concern us. However, Kirin is currently trading near the 52-week low and it appears that downside risks such as the troubles regarding the Myanmar JV and the overall market weaknesses due to COVID-19 are mostly priced in the current share price. Therefore, we would buy Kirin at these levels.


Kirin: An End to Troubles in Myanmar JV Could Unwind the Multi-Year Low Holdco Discount

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

TOPIX is constructed differently than other major indices. It has no fixed number of constituents like S&amp;P500, and it has reasonably loose rules on membership, which will soon get tighter as the TOPIX spends a few years matching the TSE Prime market section which launches 1 April 2022, but it probably will still not be tight enough to be a legitimate blue chip index. But it is what we got.There is a slew of TOPIX rebalance trades every year. There are monthly "company data" changes. Then there are quarterly changes for FFW. And there is an annual liquidity factor adjustment rebalance. On the 7th last week, the TSE announced the July FFW changes. They are bigger than many expected. And more numerous (15 dozen changes). I see a bit over US$2.5bn to sell on the down-weights. And some large trades are reasonably impactful. More below the fold.

TOPIX is constructed differently than other major indices. It has no fixed number of constituents like S&amp;P500, and it has reasonably loose rules on membership, which will soon get tighter as the TOPIX spends a few years matching the TSE Prime market section which launches 1 April 2022, but it probably will still not be tight enough to be a legitimate blue chip index. But it is what we got.There is a slew of TOPIX rebalance trades every year. There are monthly "company data" changes. Then there are quarterly changes for FFW. And there is an annual liquidity factor adjustment rebalance. On the 7th last week, the TSE announced the July FFW changes. They are bigger than many expected. And more numerous (15 dozen changes). I see a bit over US$2.5bn to sell on the down-weights. And some large trades are reasonably impactful. More below the fold. 

The weight of the evidence continues to support our mixed, but overall constructive outlook. Below we outline the basis for our outlook, and we also highlight opportunities within Real Estate and Health Care.

The weight of the evidence continues to support our mixed, but overall constructive outlook. Below we outline the basis for our outlook, and we also highlight opportunities within Real Estate and Health Care.

Global Equity Strategy: Opportunities In Real Estate and Health Care

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kirin-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:16977:1" rel="noopener">Kirin Holdings (2503 JP)</a> reported its 1Q21 results last week, with revenue and operating profit falling broadly in line with consensus estimates.</li>
<li>The company’s revenue declined by 3.6% YoY to ¥409.3bn, compared to 2.3%, 9.6%, 4.1% and 2.7% YoY in 1Q20, 2Q20, 3Q20, and 4Q20 respectively.</li>
<li>The operating profit increased by 7.5% YoY to ¥28.1bn, compared to ¥26.1bn, ¥23.4bn, ¥54.9bn, and ¥-1.4bn in 1Q20, 2Q20, 3QY20, and 4Q20 respectively. This was mainly due to lower SG&amp;A and other operating expenses.</li>
<li>The full year revenue and profit guidance remained unchanged at a revenue of ¥1,880bn and an operating profit of ¥151bn compared to consensus revenue and OP of ¥1,856bn and ¥151.4bn respectively. However, the company is still evaluating options regarding its Myanmar JV, which could lead to a significant impact on Kirin’s 2021 guidance.</li>
</ul>



Kirin Holdings (2503 JP) reported its 1Q21 results last week, with revenue and operating profit falling broadly in line with consensus estimates.
The company’s revenue declined by 3.6% YoY to ¥409.3bn, compared to 2.3%, 9.6%, 4.1% and 2.7% YoY in 1Q20, 2Q20, 3Q20, and 4Q20 respectively.
The operating profit increased by 7.5% YoY to ¥28.1bn, compared to ¥26.1bn, ¥23.4bn, ¥54.9bn, and ¥-1.4bn in 1Q20, 2Q20, 3QY20, and 4Q20 respectively. This was mainly due to lower SG&amp;A and other operating expenses.
The full year revenue and profit guidance remained unchanged at a revenue of ¥1,880bn and an operating profit of ¥151bn compared to consensus revenue and OP of ¥1,856bn and ¥151.4bn respectively. However, the company is still evaluating options regarding its Myanmar JV, which could lead to a significant impact on Kirin’s 2021 guidance.


Kirin Seems Enticing from a Holdco Perspective, but Myanmar JV Still Poses Reputational & ESG Risks

Japan

Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kyowa Kirin Co Ltd (4151 JP)

Global Energy Sector Improving -- Buying Reliance Industries Ltd, Several Others

Crude oil prices display bullish short-term reversals, resulting in bullish price and RS reversals for global Energy stocks -- add exposure.

Vermilion Research

Kirin: An End to Troubles in Myanmar JV Could Unwind the Multi-Year Low Holdco Discount

Kirin is currently trading at ¥1,982 per share, 5.5% above the past 52 week low just 7.2% above the COVID sell-off level. The market value of...

Oshadhi Kumarasiri

July TOPIX FFW Rebalancing Trade

The TOPIX July FFW rebalance is large this year, on what is generally an overlooked rebalance trade. There are several multi-hundred million...

Travis Lundy

Global Equity Strategy: Opportunities In Real Estate and Health Care

The weight of the evidence continues to support our mixed, but overall constructive outlook. We outline the basis for our outlook and also...

Vermilion Research

Kirin Seems Enticing from a Holdco Perspective, but Myanmar JV Still Poses Reputational & ESG Risks

We think the market has already overreacted to Myanmar’s JV troubles, but with the Myanmar coup still in the news, there is a chance that Kirin...

Oshadhi Kumarasiri

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)